InvestDashboard.com



RXi Pharmaceuticals Corporation (RXII)



$0.6
52 Week Low
$0.65
2017-04-28 14:02:49 MDT
$3.27
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $14,330,000Micro Cap (Less than $200M)
Analyst Recommendation:1Analysts say: Strong Buy. (1=Strong Buy, 5=Strong Sell)
Beta: 2.22 Higher Volatility Stock (beta over 1). Stock will go up more when the market goes up, and go down more when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: Unknown
5 Yr Est Growth: Unknown
Yield: 0.00%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: -14.47%
% Above 200 DayMA: -32.99%
RXII Performance 52 Weeks: -70.05%
S&P 500 Performance 52 Weeks: 13.50%
Downtrend is still intact: RXII is below both 50 and 200 day Moving Averages. Currently beyond technical death cross because 50 Day MA is below 200 Day MA. Stock is closer to 52 Week Low than 52 Week High.
RXII underperforming S&P 500 by -83.55% the last 52 Weeks.

Profile


More Valuation

Price To Book: 1.18
Great Value. Low Price to Book means better value.
EV to EBITDA: -0.19
Unknown EV to EBITDA ratio

More Info

Field Value Average Comments
% Held By InsidersN/A 17.28%Unknown.
% Held By InstitutionsN/A 62.07%Unknown.
Short % Of Float21.36% 07.02% Shorted by greater than average percent. Investors and traders do not believe in stock. But watch out for short squeezes pushing stock upwards.
Debt to EquityN/A 1.08Unknown.
Profit Margin %N/A-00.18%Unknown.
Operating Margin %-47.00%-05.28% Operating Margin less than average percent. Stock can do better than this?
Return on Equity %-91.10%-08.79% Return on Equity less than average percent. Stock can do better than this?
Return on Assets %-45.89%-01.29% Return on Assets less than average percent. Stock can do better than this?
Revenue Per Employee $1,266.67 $883,096.70 Less than average Revenue Per Employee. This stock (or industry) might not be as efficient as others? Each industry might have a different standard.
Price to Cash 1.10 5.52 Lower than average Price to Cash. Meaning that the company has a higher percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Analysts like this stock: 1 (1=Strong Buy, 5=Strong Sell)

  2. Price to Cash Ratio (1.10) is less than average. Good. Company has more cash as percentage of price than other companies.

  3. Price to Book is under 5: 1.18

CONS:
  1. Stock is Below Short Term 50DMA: -14.47%

  2. Stock is Below Long Term 200DMA: -32.99%

  3. Stock underperforming S&P 500 over last 52 weeks: -83.55%

  4. Shorted more than average: 21.36%

  5. Operating Margin is negative: -47.00%

  6. Return on Equity is negative: -91.10%

  7. Return on Assets is negative: -45.89%


Headlines


Stock Chart


InvestDashboard.com RXII: RXi Pharmaceuticals Corporation

This page updated Thu Feb 1 22:00:01 MST 2018.